BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Vegh Z, Burisch J, Pedersen N, Kaimakliotis I, Duricova D, Bortlik M, Avnstrøm S, Vinding KK, Olsen J, Nielsen KR. Incidence and initial disease course of inflammatory bowel diseases in 2011 in Europe and Australia: results of the 2011 ECCO-EpiCom inception cohort. J Crohns Colitis. 2014;8:1506-1515. [PMID: 24998983 DOI: 10.1016/j.crohns.2014.06.004] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 8.1] [Reference Citation Analysis]
Number Citing Articles
1 van Gennep S, de Boer NK, D'Haens GR, Löwenberg M. Thiopurine Treatment in Ulcerative Colitis: A Critical Review of the Evidence for Current Clinical Practice. Inflamm Bowel Dis 2017;24:67-77. [PMID: 29272488 DOI: 10.1093/ibd/izx025] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
2 Gong Y, Liu L, He X, Zhao H, Yang J, Li L, Lu A, Lin Y, Jiang M. The th17/treg immune balance in ulcerative colitis patients with two different chinese syndromes: dampness-heat in large intestine and spleen and kidney yang deficiency syndrome. Evid Based Complement Alternat Med 2015;2015:264317. [PMID: 25815027 DOI: 10.1155/2015/264317] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
3 Aniwan S, Park SH, Loftus EV. Epidemiology, Natural History, and Risk Stratification of Crohn's Disease. Gastroenterology Clinics of North America 2017;46:463-80. [DOI: 10.1016/j.gtc.2017.05.003] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
4 Tajti J, Látos M, Farkas K, Ábrahám S, Simonka Z, Paszt A, Molnár T, Lázár G. Effect of Laparoscopic Surgery on Quality of Life in Ulcerative Colitis. Journal of Laparoendoscopic & Advanced Surgical Techniques 2018;28:833-8. [DOI: 10.1089/lap.2017.0698] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
5 Marín-Jiménez I, Saro C, Díaz V, Acosta MB, Gómez-García M, Casbas AG. Epidemiology and hospital resources use in the treatment of ulcerative colitis at gastroenterology units in Spain (EPICURE study). Drugs Context 2018;7:212505. [PMID: 29535792 DOI: 10.7573/dic.212505] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
6 Weimers P, Munkholm P. The Natural History of IBD: Lessons Learned. Curr Treat Options Gastroenterol 2018;16:101-11. [PMID: 29359275 DOI: 10.1007/s11938-018-0173-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
7 Hammer T, Nielsen KR, Munkholm P, Burisch J, Lynge E. The Faroese IBD Study: Incidence of Inflammatory Bowel Diseases Across 54 Years of Population-based Data. J Crohns Colitis. 2016;10:934-942. [PMID: 26933031 DOI: 10.1093/ecco-jcc/jjw050] [Cited by in Crossref: 33] [Cited by in F6Publishing: 29] [Article Influence: 5.5] [Reference Citation Analysis]
8 Alharbi R, Almahmudi F, Makhdoom Y, Mosli M. Knowledge and attitudes of primary healthcare physicians toward the diagnosis and management of inflammatory bowel disease following an educational intervention: A comparative analysis. Saudi J Gastroenterol 2019;25:277-85. [PMID: 31187783 DOI: 10.4103/sjg.SJG_169_19] [Cited by in Crossref: 3] [Article Influence: 1.0] [Reference Citation Analysis]
9 Chen S, Liu H, Li Z, Tang J, Huang B, Zhi F, Zhao X. Epithelial PBLD attenuates intestinal inflammatory response and improves intestinal barrier function by inhibiting NF-κB signaling. Cell Death Dis 2021;12:563. [PMID: 34059646 DOI: 10.1038/s41419-021-03843-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
10 Michaelides PG, Theodoratou O, Konstantakis KN. Inflammatory bowel disease and economic activity: panel data evidence for Europe. Applied Economics Letters 2020;27:72-6. [DOI: 10.1080/13504851.2019.1680791] [Reference Citation Analysis]
11 Truffi M, Sevieri M, Morelli L, Monieri M, Mazzucchelli S, Sorrentino L, Allevi R, Bonizzi A, Zerbi P, Marchini B, Longhi E, Sampietro GM, Colombo F, Prosperi D, Colombo M, Corsi F. Anti-MAdCAM-1-Conjugated Nanocarriers Delivering Quantum Dots Enable Specific Imaging of Inflammatory Bowel Disease. Int J Nanomedicine 2020;15:8537-52. [PMID: 33173291 DOI: 10.2147/IJN.S264513] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
12 Molina-Infante J, Gonzalez-Cordero PL, Ferreira-Nossa HC, Mata-Romero P, Lucendo AJ, Arias A. Rising incidence and prevalence of adult eosinophilic esophagitis in midwestern Spain (2007-2016). United European Gastroenterol J 2018;6:29-37. [PMID: 29435311 DOI: 10.1177/2050640617705913] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
13 Aniwan S, Limsrivilai J, Pongprasobchai S, Pausawasdi N, Prueksapanich P, Kongtub N, Rerknimitr R. Temporal trend in the natural history of ulcerative colitis in a country with a low incidence of ulcerative colitis from 2000 through 2018. Intest Res 2021;19:186-93. [PMID: 32806871 DOI: 10.5217/ir.2020.00028] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
14 Zhang FM, Xu CF, Shan GD, Chen HT, Xu GQ. Is gallstone disease associated with inflammatory bowel diseases? A meta-analysis. J Dig Dis 2015;16:634-41. [PMID: 26332254 DOI: 10.1111/1751-2980.12286] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
15 Kunovszki P, Milassin Á, Gimesi-Országh J, Takács P, Szántó K, Bálint A, Farkas K, Borsi A, Lakatos PL, Szamosi T, Molnár T. Epidemiology, mortality and prevalence of colorectal cancer in ulcerative colitis patients between 2010-2016 in Hungary - a population-based study. PLoS One 2020;15:e0233238. [PMID: 32407408 DOI: 10.1371/journal.pone.0233238] [Reference Citation Analysis]
16 Chaparro M, Barreiro-de Acosta M, Benítez JM, Cabriada JL, Casanova MJ, Ceballos D, Esteve M, Fernández H, Ginard D, Gomollón F, Lorente R, Nos P, Riestra S, Rivero M, Robledo P, Rodríguez C, Sicilia B, Torrella E, Garre A, García-Esquinas E, Rodríguez-Artalejo F, Gisbert JP; EpidemIBD study group of GETECCU. EpidemIBD: rationale and design of a large-scale epidemiological study of inflammatory bowel disease in Spain. Therap Adv Gastroenterol 2019;12:1756284819847034. [PMID: 31205485 DOI: 10.1177/1756284819847034] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
17 Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720-727. [PMID: 26323879 DOI: 10.1038/nrgastro.2015.150] [Cited by in Crossref: 766] [Cited by in F6Publishing: 707] [Article Influence: 109.4] [Reference Citation Analysis]
18 Lan D, Niu J, Miao J, Dong X, Wang H, Yang G, Wang K, Miao Y. Expression of guanylate cyclase-C, guanylin, and uroguanylin is downregulated proportionally to the ulcerative colitis disease activity index. Sci Rep. 2016;6:25034. [PMID: 27125248 DOI: 10.1038/srep25034] [Cited by in Crossref: 16] [Cited by in F6Publishing: 18] [Article Influence: 2.7] [Reference Citation Analysis]
19 Zhu Z, Mei Z, Guo Y, Wang G, Wu T, Cui X, Huang Z, Zhu Y, Wen D, Song J, He H, Xu W, Cui L, Liu C. Reduced Risk of Inflammatory Bowel Disease-associated Colorectal Neoplasia with Use of Thiopurines: a Systematic Review and Meta-analysis. J Crohns Colitis. 2018;12:546-558. [PMID: 29370346 DOI: 10.1093/ecco-jcc/jjy006] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 5.3] [Reference Citation Analysis]
20 Chaparro M, Garre A, Núñez Ortiz A, Diz-Lois Palomares MT, Rodríguez C, Riestra S, Vela M, Benítez JM, Fernández Salgado E, Sánchez Rodríguez E, Hernández V, Ferreiro-Iglesias R, Ponferrada Díaz Á, Barrio J, Huguet JM, Sicilia B, Martín-Arranz MD, Calvet X, Ginard D, Alonso-Abreu I, Fernández-Salazar L, Varela Trastoy P, Rivero M, Vera-Mendoza I, Vega P, Navarro P, Sierra M, Cabriada JL, Aguas M, Vicente R, Navarro-Llavat M, Echarri A, Gomollón F, Guerra Del Río E, Piñero C, Casanova MJ, Spicakova K, Ortiz de Zarate J, Torrella Cortés E, Gutiérrez A, Alonso-Galán H, Hernández-Martínez Á, Marrero JM, Lorente Poyatos R, Calafat M, Martí Romero L, Robledo P, Bosch O, Jiménez N, Esteve Comas M, Duque JM, Fuentes Coronel AM, Josefa Sampedro M, Sesé Abizanda E, Herreros Martínez B, Pozzati L, Fernández Rosáenz H, Crespo Suarez B, López Serrano P, Lucendo AJ, Muñoz Vicente M, Bermejo F, Ramírez Palanca JJ, Menacho M, Carmona A, Camargo R, Torra Alsina S, Maroto N, Nerín de la Puerta J, Castro E, Marín-Jiménez I, Botella B, Sapiña A, Cruz N, Forcelledo JLF, Bouhmidi A, Castaño-Milla C, Opio V, Nicolás I, Kutz M, Abraldes Bechiarelli A, Gordillo J, Ber Y, Torres Domínguez Y, Novella Durán MT, Rodríguez Mondéjar S, Martínez-Cerezo FJ, Kolle L, Sabat M, Ledezma C, Iyo E, Roncero Ó, Irisarri R, Lluis L, Blázquez Gómez I, Zapata EM, José Alcalá M, Martínez Pascual C, Montealegre M, Mata L, Monrobel A, Hernández Camba A, Hernández L, Tejada M, Mir A, Galve ML, Soler M, Hervías D, Gómez-Valero JA, Barreiro-de Acosta M, Rodríguez-Artalejo F, García-Esquinas E, Gisbert JP, On Behalf Of The EpidemIBD Study Group Of Geteccu. Incidence, Clinical Characteristics and Management of Inflammatory Bowel Disease in Spain: Large-Scale Epidemiological Study. J Clin Med 2021;10:2885. [PMID: 34209680 DOI: 10.3390/jcm10132885] [Reference Citation Analysis]
21 Lai HC, Chang CH, Cheng KS, Chen TW, Tsai YY, Chou JW. QuantiFERON-TB Gold Test Conversion Is Associated with Active Tuberculosis Development in Inflammatory Bowel Disease Patients Treated with Biological Agents: An Experience of a Medical Center in Taiwan. Gastroenterol Res Pract 2019;2019:7132875. [PMID: 31781198 DOI: 10.1155/2019/7132875] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
22 Purnamawati K, Ong JA, Deshpande S, Tan WK, Masurkar N, Low JK, Drum CL. The Importance of Sex Stratification in Autoimmune Disease Biomarker Research: A Systematic Review. Front Immunol 2018;9:1208. [PMID: 29915581 DOI: 10.3389/fimmu.2018.01208] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
23 Elbadry M, Nour MO, Hussien M, Ghoneem EA, Medhat MA, Shehab H, Galal S, Eltabbakh M, El-raey F, Negm M, Afify S, Abdelhamed W, Sherief A, Abdelaziz A, Abo Elkasem M, Mahrous A, Kamal G, Maher M, Abdel-hameed O, Elbasuny A, El-zayyadi I, Bassiony A, Moussa A, Bedewy E, Elfert A, El Kassas M. Clinico-Epidemiological Characteristics of Patients With Inflammatory Bowel Disease in Egypt: A Nationwide Multicenter Study. Front Med 2022;9:867293. [DOI: 10.3389/fmed.2022.867293] [Reference Citation Analysis]
24 Mak WY, Zhao M, Ng SC, Burisch J. The epidemiology of inflammatory bowel disease: East meets west. J Gastroenterol Hepatol. 2020;35:380-389. [PMID: 31596960 DOI: 10.1111/jgh.14872] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 14.7] [Reference Citation Analysis]
25 Agrawal M, Corn G, Shrestha S, Nielsen NM, Frisch M, Colombel JF, Jess T. Inflammatory bowel diseases among first-generation and second-generation immigrants in Denmark: a population-based cohort study. Gut 2021;70:1037-43. [PMID: 32895335 DOI: 10.1136/gutjnl-2020-321798] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
26 Qualter P, Rouncefield-Swales A, Bray L, Blake L, Allen S, Probert C, Crook K, Carter B. Depression, anxiety, and loneliness among adolescents and young adults with IBD in the UK: the role of disease severity, age of onset, and embarrassment of the condition. Qual Life Res 2021;30:497-506. [PMID: 32997335 DOI: 10.1007/s11136-020-02653-9] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Kurti Z, Vegh Z, Golovics PA, Fadgyas-Freyler P, Gecse KB, Gonczi L, Gimesi-Orszagh J, Lovasz BD, Lakatos PL. Nationwide prevalence and drug treatment practices of inflammatory bowel diseases in Hungary: A population-based study based on the National Health Insurance Fund database. Dig Liver Dis. 2016;48:1302-1307. [PMID: 27481587 DOI: 10.1016/j.dld.2016.07.012] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 3.5] [Reference Citation Analysis]
28 Chetcuti Zammit S, Ellul P, Girardin G, Valpiani D, Nielsen KR, Olsen J, Goldis A, Lazar D, Shonová O, Nováková M, Sebastian S, Whitehead E, Carmona A, Martinez-Cadilla J, Dahlerup JF, Kievit ALH, Thorsgaard N, Katsanos KH, Christodoulou DK, Magro F, Salupere R, Pedersen N, Kjeldsen J, Carlsen K, Ioannis K, Bergemalm D, Halfvarson J, Duricova D, Bortlik M, Collin P, Oksanen P, Kiudelis G, Kupcinskas L, Kudsk K, Andersen V, O'Morain C, Bailey Y, Doron S, Shmuel O, Almer S, Arebi N, Misra R, Čuković-Čavka S, Brinar M, Munkholm P, Vegh Z, Burisch J. Vitamin D deficiency in a European inflammatory bowel disease inception cohort: an Epi-IBD study. Eur J Gastroenterol Hepatol 2018;30:1297-303. [PMID: 30134383 DOI: 10.1097/MEG.0000000000001238] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 5.3] [Reference Citation Analysis]
29 Tavakoli P, Vollmer-Conna U, Hadzi-Pavlovic D, Grimm MC. A Review of Inflammatory Bowel Disease: A Model of Microbial, Immune and Neuropsychological Integration. Public Health Rev 2021;42:1603990. [PMID: 34692176 DOI: 10.3389/phrs.2021.1603990] [Reference Citation Analysis]
30 Gareb B, Posthumus S, Beugeling M, Koopmans P, Touw DJ, Dijkstra G, Kosterink JGW, Frijlink HW. Towards the Oral Treatment of Ileo-Colonic Inflammatory Bowel Disease with Infliximab Tablets: Development and Validation of the Production Process. Pharmaceutics 2019;11:E428. [PMID: 31450748 DOI: 10.3390/pharmaceutics11090428] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
31 Nguyen NH, Fumery M, Dulai PS, Prokop LJ, Sandborn WJ, Murad MH, Singh S. Comparative efficacy and tolerability of pharmacological agents for management of mild to moderate ulcerative colitis: a systematic review and network meta-analyses. Lancet Gastroenterol Hepatol 2018;3:742-53. [PMID: 30122356 DOI: 10.1016/S2468-1253(18)30231-0] [Cited by in Crossref: 15] [Cited by in F6Publishing: 9] [Article Influence: 3.8] [Reference Citation Analysis]
32 Verdon C, Reinglas J, Coulombe J, Gonczi L, Bessissow T, Afif W, Vutcovici M, Wild G, Seidman EG, Bitton A, Brassard P, Lakatos PL. No Change in Surgical and Hospitalization Trends Despite Higher Exposure to Anti-Tumor Necrosis Factor in Inflammatory Bowel Disease in the Québec Provincial Database From 1996 to 2015. Inflamm Bowel Dis 2021;27:655-61. [PMID: 32676662 DOI: 10.1093/ibd/izaa166] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
33 Lophaven SN, Lynge E, Burisch J. The incidence of inflammatory bowel disease in Denmark 1980-2013: a nationwide cohort study. Aliment Pharmacol Ther. 2017;45:961-972. [PMID: 28229470 DOI: 10.1111/apt.13971] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 13.8] [Reference Citation Analysis]
34 Jarmuż A, Zielińska M, Storr M, Fichna J. Emerging treatments in Neurogastroenterology: Perspectives of guanylyl cyclase C agonists use in functional gastrointestinal disorders and inflammatory bowel diseases. Neurogastroenterol Motil 2015;27:1057-68. [PMID: 25930667 DOI: 10.1111/nmo.12574] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
35 Molina-Infante J, Schoepfer AM, Lucendo AJ, Dellon ES. Eosinophilic esophagitis: What can we learn from Crohn's disease? United European Gastroenterol J 2017;5:762-72. [PMID: 29026590 DOI: 10.1177/2050640616672953] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
36 Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, Walker G, Bewshea C, Kennedy NA, Ahmad T, Goodhand J. Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterol 2021;12:461-70. [PMID: 34712463 DOI: 10.1136/flgastro-2019-101369] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
37 Bhatia R, Yeoh SW, Vaz K, Studd C, Wilson J, Bell S, Otahal P, Venn A. Inflammatory bowel disease incidence, prevalence and 12-month initial disease course in Tasmania, Australia. Intern Med J 2019;49:622-30. [PMID: 30230160 DOI: 10.1111/imj.14111] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
38 Thomas T, Chandan JS, Li VSW, Lai CY, Tang W, Bhala N, Kaplan GG, Ng SC, Ghosh S. Global smoking trends in inflammatory bowel disease: A systematic review of inception cohorts. PLoS One 2019;14:e0221961. [PMID: 31545811 DOI: 10.1371/journal.pone.0221961] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
39 Fumery M, Singh S, Dulai PS, Gower-Rousseau C, Peyrin-Biroulet L, Sandborn WJ. Natural History of Adult Ulcerative Colitis in Population-based Cohorts: A Systematic Review. Clin Gastroenterol Hepatol. 2018;16:343-356.e3. [PMID: 28625817 DOI: 10.1016/j.cgh.2017.06.016] [Cited by in Crossref: 116] [Cited by in F6Publishing: 101] [Article Influence: 23.2] [Reference Citation Analysis]
40 Gordon H, Langholz E. The EpiCom Survey-Registries Across Europe, Epidemiological Research and Beyond. J Crohns Colitis. 2017;11:1019-1021. [PMID: 28158624 DOI: 10.1093/ecco-jcc/jjx013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
41 Hammer T, Lophaven SN, Nielsen KR, von Euler-Chelpin M, Weihe P, Munkholm P, Burisch J, Lynge E. Inflammatory bowel diseases in Faroese-born Danish residents and their offspring: further evidence of the dominant role of environmental factors in IBD development. Aliment Pharmacol Ther 2017;45:1107-14. [PMID: 28176348 DOI: 10.1111/apt.13975] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 3.2] [Reference Citation Analysis]
42 Mak JWY, Ng SC. Epidemiology of fibrostenosing inflammatory bowel disease. J Dig Dis 2020;21:332-5. [PMID: 32105396 DOI: 10.1111/1751-2980.12853] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
43 Bennett AL, Munkholm P, Andrews JM. Tools for primary care management of inflammatory bowel disease: Do they exist? World J Gastroenterol 2015; 21(15): 4457-4465 [PMID: 25914455 DOI: 10.3748/wjg.v21.i15.4457] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
44 Piscaglia AC, Lopetuso LR, Laterza L, Gerardi V, Sacchini E, Leoncini E, Boccia S, Stefanelli ML, Gasbarrini A, Armuzzi A. Epidemiology of inflammatory bowel disease in the Republic of San Marino: The “EPIMICI – San Marino” study. Digestive and Liver Disease 2019;51:218-25. [DOI: 10.1016/j.dld.2018.08.016] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
45 Kokoszko-bilska A, Sobkiewicz S, Fichna J. Inflammatory bowel diseases and reproductive health. Pharmacological Reports 2016;68:859-64. [DOI: 10.1016/j.pharep.2016.03.009] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
46 Su HY, Gupta V, Day AS, Gearry RB. Rising Incidence of Inflammatory Bowel Disease in Canterbury, New Zealand. Inflamm Bowel Dis. 2016;22:2238-2244. [PMID: 27482976 DOI: 10.1097/mib.0000000000000829] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 6.0] [Reference Citation Analysis]
47 Truffi M, Colombo M, Peñaranda-Avila J, Sorrentino L, Colombo F, Monieri M, Collico V, Zerbi P, Longhi E, Allevi R, Prosperi D, Corsi F. Nano-targeting of mucosal addressin cell adhesion molecule-1 identifies bowel inflammation foci in murine model. Nanomedicine (Lond) 2017;12:1547-60. [PMID: 28621606 DOI: 10.2217/nnm-2017-0004] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
48 Hu Y, Ye Z, Wu M, She Y, Li L, Xu Y, Qin K, Hu Z, Yang M, Lu F, Ye Q. The Communication Between Intestinal Microbiota and Ulcerative Colitis: An Exploration of Pathogenesis, Animal Models, and Potential Therapeutic Strategies. Front Med (Lausanne) 2021;8:766126. [PMID: 34966755 DOI: 10.3389/fmed.2021.766126] [Reference Citation Analysis]
49 Ratajczak AE, Szymczak-Tomczak A, Rychter AM, Zawada A, Dobrowolska A, Krela-Kaźmierczak I. Impact of Cigarette Smoking on the Risk of Osteoporosis in Inflammatory Bowel Diseases. J Clin Med 2021;10:1515. [PMID: 33916465 DOI: 10.3390/jcm10071515] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
50 Vegh Z, Kurti Z, Lakatos PL. Epidemiology of inflammatory bowel diseases from west to east. J Dig Dis. 2017;18:92-98. [PMID: 28102560 DOI: 10.1111/1751-2980.12449] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 8.6] [Reference Citation Analysis]
51 Galeone C, Pelucchi C, Barbera G, Citterio C, La Vecchia C, Franchi A. Crohn’s disease in Italy: A critical review of the literature using different data sources. Digestive and Liver Disease 2017;49:459-66. [DOI: 10.1016/j.dld.2016.12.033] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
52 Singh S, Feuerstein JD, Binion DG, Tremaine WJ. AGA Technical Review on the Management of Mild-to-Moderate Ulcerative Colitis. Gastroenterology 2019;156:769-808.e29. [PMID: 30576642 DOI: 10.1053/j.gastro.2018.12.008] [Cited by in Crossref: 39] [Cited by in F6Publishing: 35] [Article Influence: 9.8] [Reference Citation Analysis]
53 Danese S, Fiorino G, Mary J, Lakatos PL, D’haens G, Moja L, D’hoore A, Panes J, Reinisch W, Sandborn WJ, Travis SP, Vermeire S, Peyrin-biroulet L, Colombel J. Development of Red Flags Index for Early Referral of Adults with Symptoms and Signs Suggestive of Crohn’s Disease: An IOIBD Initiative. ECCOJC 2015;9:601-6. [DOI: 10.1093/ecco-jcc/jjv067] [Cited by in Crossref: 44] [Cited by in F6Publishing: 42] [Article Influence: 6.3] [Reference Citation Analysis]
54 Burisch J, Vegh Z, Katsanos KH, Christodoulou DK, Lazar D, Goldis A, O'Morain C, Fernandez A, Pereira S, Myers S, Sebastian S, Pedersen N, Olse J, Rubek Nielsen K, Schwartz D, Odes S, Almer S, Halfvarson J, Turk N, Cukovic-Cavka S, Nikulina I, Belousova E, Duricova D, Bortlik M, Shonová O, Salupere R, Barros L, Magro F, Jonaitis L, Kupcinskas L, Turcan S, Kaimakliotis I, Ladefoged K, Kudsk K, Andersen V, Vind I, Thorsgaard N, Oksanen P, Collin P, Dal Piaz G, Santini A, Niewiadomski O, Bell S, Moum B, Arebi N, Kjeldsen J, Carlsen K, Langholz E, Lakatos PL, Munkholm P, Gerdes LU, Dahlerup JF; EpiCom study group. Occurrence of Anaemia in the First Year of Inflammatory Bowel Disease in a European Population-based Inception Cohort-An ECCO-EpiCom Study. J Crohns Colitis 2017;11:1213-22. [PMID: 28575481 DOI: 10.1093/ecco-jcc/jjx077] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
55 Vegh Z, Burisch J, Pedersen N, Kaimakliotis I, Duricova D, Bortlik M, Vinding KK, Avnstrøm S, Olsen J, Nielsen KR, Katsanos KH, Tsianos EV, Lakatos L, Schwartz D, Odes S, D’incà R, Beltrami M, Kiudelis G, Kupcinskap L, Jucov A, Turcan S, Barros LF, Magro F, Lazar D, Goldis A, de Castro L, Hernandez V, Niewiadomski O, Bell S, Langholz E, Munkholm P, Lakatos PL; for the EpiCom-group. Treatment Steps, Surgery, and Hospitalization Rates During the First Year of Follow-up in Patients with Inflammatory Bowel Diseases from the 2011 ECCO-Epicom Inception Cohort. ECCOJC 2015;9:747-53. [DOI: 10.1093/ecco-jcc/jjv099] [Cited by in Crossref: 29] [Cited by in F6Publishing: 26] [Article Influence: 4.1] [Reference Citation Analysis]
56 Kurti Z, Ilias A, Gonczi L, Vegh Z, Fadgyas-Freyler P, Korponay G, Golovics PA, Lovasz BD, Lakatos PL. Therapeutic preferences and outcomes in newly diagnosed patients with Crohn's diseases in the biological era in Hungary: a nationwide study based on the National Health Insurance Fund database. BMC Gastroenterol 2018;18:23. [PMID: 29378524 DOI: 10.1186/s12876-018-0746-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Kalaria R, Desai D, Abraham P, Joshi A, Gupta T, Shah S. Temporal Change in Phenotypic Behaviour in Patients with Crohn's Disease: Do Indian Patients Behave Differently from Western and Other Asian Patients? J Crohns Colitis. 2016;10:255-261. [PMID: 26519461 DOI: 10.1093/ecco-jcc/jjv202] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.9] [Reference Citation Analysis]
58 Gustafsson I, Repo M, Popp A, Kaukinen K, Hiltunen P, Arvola T, Taavela J, Vornanen M, Kivelä L, Kurppa K. Prevalence and diagnostic outcomes of children with duodenal lesions and negative celiac serology. Dig Liver Dis 2020;52:289-95. [PMID: 31899123 DOI: 10.1016/j.dld.2019.11.011] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
59 Ma C, Jeyarajah J, Guizzetti L, Parker CE, Singh S, Dulai PS, D'Haens GR, Sandborn WJ, Feagan BG, Jairath V. Modeling Endoscopic Improvement after Induction Treatment With Mesalamine in Patients With Mild-to-Moderate Ulcerative Colitis. Clin Gastroenterol Hepatol 2022;20:447-454.e1. [PMID: 33279779 DOI: 10.1016/j.cgh.2020.11.040] [Reference Citation Analysis]
60 Chou JW, Lai HC, Chang CH, Cheng KS, Feng CL, Chen TW. Epidemiology and Clinical Outcomes of Inflammatory Bowel Disease: A Hospital-Based Study in Central Taiwan. Gastroenterol Res Pract. 2019;2019:4175923. [PMID: 31312216 DOI: 10.1155/2019/4175923] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]